CN111542345B - 氯毒素剂及其用途 - Google Patents

氯毒素剂及其用途 Download PDF

Info

Publication number
CN111542345B
CN111542345B CN201880073331.4A CN201880073331A CN111542345B CN 111542345 B CN111542345 B CN 111542345B CN 201880073331 A CN201880073331 A CN 201880073331A CN 111542345 B CN111542345 B CN 111542345B
Authority
CN
China
Prior art keywords
chlorotoxin
moiety
cancer
polypeptide
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880073331.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111542345A (zh
Inventor
S·麦戈尼格尔
U·马朱姆德
M·H·D·波坦玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Corp of North America
Original Assignee
Eisai Corp of North America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Corp of North America filed Critical Eisai Corp of North America
Publication of CN111542345A publication Critical patent/CN111542345A/zh
Application granted granted Critical
Publication of CN111542345B publication Critical patent/CN111542345B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0026—Acridine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Insects & Arthropods (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880073331.4A 2017-09-15 2018-09-14 氯毒素剂及其用途 Active CN111542345B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762559432P 2017-09-15 2017-09-15
US62/559,432 2017-09-15
PCT/US2018/051165 WO2019055840A1 (en) 2017-09-15 2018-09-14 CHLOROTOXIN AGENTS AND USES THEREOF

Publications (2)

Publication Number Publication Date
CN111542345A CN111542345A (zh) 2020-08-14
CN111542345B true CN111542345B (zh) 2025-02-25

Family

ID=65724060

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880073331.4A Active CN111542345B (zh) 2017-09-15 2018-09-14 氯毒素剂及其用途

Country Status (5)

Country Link
US (1) US11826399B2 (enExample)
EP (1) EP3681540A4 (enExample)
JP (1) JP7409741B2 (enExample)
CN (1) CN111542345B (enExample)
WO (1) WO2019055840A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
US11826399B2 (en) 2017-09-15 2023-11-28 Eisai Inc. Chlorotoxin agents and uses thereof
US11866466B2 (en) 2017-12-19 2024-01-09 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
CN113073131B (zh) * 2021-03-25 2021-12-14 苏州健雄职业技术学院 一种基于纳米银和锚定磷脂双层膜的肝细胞癌核酸标记的电化学生物传感器

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136769A1 (en) * 2016-02-04 2017-08-10 Eisai R&D Management Co., Ltd. Peptide drug conjugates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
WO2003000203A2 (en) * 2001-06-26 2003-01-03 Uab Research Foundation Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
EP2431385A3 (en) 2002-05-31 2012-07-04 Morphotek, Inc. Combination therapy with chlorotoxin
ES2339683T3 (es) 2004-04-06 2010-05-24 Transmolecular, Inc. Diagnostico y tratamiento de canceres de celulas mieloides y linfoides.
US20080153746A1 (en) 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
WO2007117467A2 (en) 2006-03-31 2007-10-18 Transmolecular, Inc. Use of tm-601 for the diagnosis and treatment of tumors
US20110091380A1 (en) 2007-08-07 2011-04-21 Transmolecular, Inc. Chlorotoxins as drug carriers
WO2009049184A2 (en) 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
US8470607B2 (en) 2008-03-20 2013-06-25 Morphotek, Inc. Inhibition of angiogenesis
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
WO2013003507A1 (en) * 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
US10765625B2 (en) 2016-03-15 2020-09-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
US11826399B2 (en) 2017-09-15 2023-11-28 Eisai Inc. Chlorotoxin agents and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136769A1 (en) * 2016-02-04 2017-08-10 Eisai R&D Management Co., Ltd. Peptide drug conjugates

Also Published As

Publication number Publication date
WO2019055840A1 (en) 2019-03-21
JP2020534276A (ja) 2020-11-26
US20200206312A1 (en) 2020-07-02
CN111542345A (zh) 2020-08-14
JP7409741B2 (ja) 2024-01-09
EP3681540A1 (en) 2020-07-22
EP3681540A4 (en) 2021-05-19
US11826399B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
CN111542345B (zh) 氯毒素剂及其用途
CN106995493B (zh) 氯毒素多肽和结合物及其应用
CN110913908B (zh) 靶向msln的三特异性蛋白质及使用方法
CN110913903B (zh) 聚糖相互作用化合物和使用方法
CN121159691A (zh) 间皮素结合蛋白质
CN105658240A (zh) 用于缀合可活化抗体的组合物和方法
CN107531776B (zh) 用于诊断和治疗癌症的组合物和方法
EP3261678B1 (en) Antibody-urease conjugates for therapeutic purposes
CN114269389B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
EP3271401A1 (en) Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
US20220411514A1 (en) Anti-gal3 antibodies and methods of use for insulin resistance
JP2021113196A (ja) 標的型薬物デリバリーのための自己集合性分子
JP2021073179A (ja) アポトーシスを誘導するための組成物及び方法
JP2023504199A (ja) Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
JP2022541650A (ja) ペプチド核酸系の作用物質を用いて癌を治療するための方法および組成物
CN105873950A (zh) 用于治疗和诊断癌症的抗s100a7抗体
AU2013274144A1 (en) Compositions and methods for treating cancer
WO2025150052A1 (en) Targeted delivery of drug conjugates to schwann cells and treatment methods in schwann cell-related diseases
ES2747836T3 (es) Métodos y productos para prevenir y/o tratar el cáncer metastásico
CN120813387A (zh) 抗ceacam5免疫缀合物用于治疗表达ceacam5的神经内分泌癌症的用途
WO2015042275A1 (en) Methods and compositions for imaging disorders using polyspecific agents
KR20210020006A (ko) 암을 진단 및 치료하기 위한 조성물 및 방법
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
CN120112554A (zh) 整合素α10抗体药物偶联物
TW202525345A (zh) 抗psma adc接合物組成物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant